retatrutide clinical trial malaysia UK 2026: Phase 3 Results Triple hormone receptor agonist retatrutide

Mounjaro (tirzepatide): A GLP-1/GIP dual agonist medication indicated for type 2 diabetes, while its counterpart Zepbound focuses on weight loss

Recent post mortem studies revealed that GLP-1R expression was downregulated in the dorsal lateral prefrontal cortex and hippocampus of patients suffering from mood disorders, and those changes further correlated with an elevated body mass index (BMI) [79]

CrossRef Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition

While both drugs lead to significant weight reduction, Retatrutides unique mechanism targets specific high-risk metabolic conditions more aggressively: This dual vs

Others need more time at each tier

I, I, I Im seeing it from both sides